Adalimumab is the first fully humanized monoclonal anti-tumor necrosis factor alpha (TNF-α) antibody. This drug has been shown to be of benefit in patients with inflammatory diseases in which TNF-α is involved, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn`s disease. As the use of adalimumab is becoming more widespread, cutaneous side effects are being